<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/28/2022 7:08:24 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 3f231abc-3316-4aef-8ae2-0ef4409a3850 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:olma="http://www.olma.com/20220228" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityCentralIndexKey" id="Tc_PI4hqfS6XkO1wbuMZGAhKA_2_1">0001750284</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:AmendmentFlag" id="Tc_GNnYhnNgVkmCIYp7xUfV1w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="olma-20220228.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001750284</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:1.0pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_763a8419_9041_4758_840c_8251462c2283"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:16pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:DocumentType" id="Narr_qKXW4eClz0OHYKhqFf4aCg"><b style="color:#212529;font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b><b style="color:#212529;font-weight:bold;"><br /></b><b style="color:#212529;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-size:9pt;font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_VFUhRdXkgECRcx_O2um96A"><b style="color:#212529;font-size:9pt;font-weight:bold;">February 28, 2022</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:16pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityRegistrantName" id="Narr_WTjzzajm3E-gXmb2jsiqYg"><b style="color:#212529;font-weight:bold;">Olema Pharmaceuticals,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_65c9dbe8_9374_44c2_b9fb_ab4e0d275874"></a><a id="Tc_XTLr09XWIkSf4UcRwXn6zA_2_0"></a><a id="Tc_c6kjX23GJ02NCaoSPQsjgQ_2_1"></a><a id="Tc_eq-lJS2bBEmVFQbxoj9lTQ_2_2"></a><a id="Tc_YgVw2HpakkuU9Seaf5A3mQ_3_0"></a><a id="Tc_1D4AdPxYv0ypNTGwlSck7A_3_1"></a><a id="Tc_ngTIYadPNEyU9OkYlTn_Kg_3_2"></a><a id="Tc_jNkeYalxQ0CNSD3yD5PTIg_4_0"></a><a id="Tc_MpsJEcjjh0eHNO0fznDZIA_5_0"></a><a id="Tc_qOoD87mFP0uN2i34eN_L-Q_6_0"></a><a id="Tc_cUBPvJBt_kKQhlpIzh6zNw_6_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_V3CvUvT9g0-NCDzdDLiVRw_1_0"><b style="color:#212529;font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityFileNumber" id="Tc_lKrgjh31LUqFr8PoqY83gQ_1_1"><b style="color:#212529;font-size:9pt;font-weight:bold;">001-39712</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityTaxIdentificationNumber" id="Tc_n3VAgHHqdESY4Ur4vYLAwg_1_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">30-0409740</b></ix:nonNumeric></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr style="height:20.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityAddressAddressLine1" id="Narr_lHYi5EhlE0SoFe_XD_lRYg"><b style="font-size:9pt;font-weight:bold;">512 2nd Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityAddressAddressLine2" id="Narr_aMKwBzNYBEalHmNYDv20FA"><b style="font-size:9pt;font-weight:bold;">4th Floor</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityAddressCityOrTown" id="Narr_AMszRsrvnkaxc1wcj9iysg"><b style="font-size:9pt;font-weight:bold;">San Francisco</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_n4NCpQMYI06aabyMRerNZQ"><b style="font-size:9pt;font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:EntityAddressPostalZipCode" id="Tc_3mWmEhRXOUWoPw9BfBjcDA_5_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">94107</b></ix:nonNumeric></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:CityAreaCode" id="Narr_FaNfMKNj60KBlI04wSEKVw"><b style="color:#212529;font-size:9pt;font-weight:bold;">415</b></ix:nonNumeric><b style="color:#212529;font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:LocalPhoneNumber" id="Narr_oCmB6MMczUaXtaXEsWvyRQ"><b style="color:#212529;font-size:9pt;font-weight:bold;">651-3316</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-weight:bold;">Not Applicable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Former name or former address, if changed since last report)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_MEj-rxAReEWE_B5yD6iaMA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_mOYZAXyFCUG8EpRMqlflsw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_8K_6P-LZ_EOB6oZl3TPN5Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_8UGsqL0gt06i8kCIBxwtdg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_d3056176_1ba2_4670_8738_084ba44b4c46"></a><a id="Tc_q3BpNvxSBEaNjTvaeBNqOA_1_1"></a><a id="Tc_6NaZOvH2VUa2W9vhhaIULg_1_2"></a><a id="Tc_KyJyuz0kRka-vMy0jtN2VA_2_0"></a><a id="Tc_1IG2kQyVJUCXdq5PGLDE5A_2_1"></a><a id="Tc_8FhMBWvwlkCHTLX1_nccxQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b></p></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:19.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:40.2%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on which registered</b></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:Security12bTitle" id="Tc_6ocD8bxG2EGHlrowkOxvrg_3_0"><b style="color:#212529;font-size:9pt;font-weight:bold;">Common Stock, $0.0001 par value per share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" name="dei:TradingSymbol" id="Tc_ky0D7IyqJU6JFLkN3bAsKQ_3_1"><b style="color:#212529;font-size:9pt;font-weight:bold;">OLMA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_6V5N7EUSWEaDrvjV7gPtug_3_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_2_28_2022_To_2_28_2022_L43xxpfhoEKKVjIoxF-SrQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_8dWhCLXCHEWyU-OhMMxcPg"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#212529;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#212529;font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:6pt 0pt 0pt 0pt;"><span style="color:#212529;font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1b9c10d3_f07c_4835_bfaf_2f56a2c81277"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;2.02</b></span>Results of Operations and Financial Condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">On February 28, 2022, Olema Pharmaceuticals,&#160;Inc. reported its financial results for the year ended December 31, 2021. A copy of the press release is furnished pursuant to Item&#160;2.02 as Exhibit&#160;99.1 hereto and is incorporated herein by reference.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The information in this Item&#160;2.02, including the press release attached as Exhibit&#160;99.1 hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section&#160;11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Olema Pharmaceuticals,&#160;Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01</b></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.92%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:85.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="olma-20220228xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Press release, dated February 28, 2022, of Olema Pharmaceuticals,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        104</span></p></td><td style="vertical-align:bottom;width:1.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_2b836277_7304_44db_a434_b69a1695dccc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk64480706"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">OLEMA PHARMACEUTICALS,&#160;INC</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dated: February 28, 2022</p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ John B. Moriarty,&#160;Jr.</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:47.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">John B. Moriarty,&#160;Jr.</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Executive Vice President, Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "olma-20220228x8k.htm", "description": "8-K", "secsgml_size_bytes": 38273}]
{"company-data": {"conformed-name": "Olema Pharmaceuticals, Inc.", "cik": "0001750284", "assigned-sic": "2834", "irs-number": "300409740", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39712", "film-number": "22690447"}, "business-address": {"street1": "512 2ND STREET, 4TH FLOOR", "city": "SAN FRANCISCO", "state": "CA", "zip": "94107", "phone": "(415) 651-3316"}, "mail-address": {"street1": "512 2ND STREET, 4TH FLOOR", "city": "SAN FRANCISCO", "state": "CA", "zip": "94107"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 28, 2022
Olema Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
001-39712
30-0409740
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
512 2nd Street
,
4th Floor
​
​
San Francisco
,
California
​
94107
(Address of principal executive offices)
​
(Zip Code)
​
(
415
)
651-3316
(Registrant's Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
​
​
​
​
​
Trading
Name of each exchange
Title of each class
Symbol(s)
on which registered
Common Stock, $0.0001 par value per share
OLMA
The Nasdaq Global Select Market
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
Item 2.02
Results of Operations and Financial Condition.
On February 28, 2022, Olema Pharmaceuticals, Inc. reported its financial results for the year ended December 31, 2021. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
The information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Olema Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
​
​
​
Item 9.01
​
Financial Statements and Exhibits.
(d) Exhibits.
​
​
Exhibit No.
Description
99.1
​
Press release, dated February 28, 2022, of Olema Pharmaceuticals, Inc.
104
​
Cover Page Interactive Data File (embedded within the Inline XBRL document).
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
OLEMA PHARMACEUTICALS, INC
​
​
Dated: February 28, 2022
​
​
​
By:
/s/ John B. Moriarty, Jr.
John B. Moriarty, Jr.
Executive Vice President, Chief Legal Officer and Corporate Secretary
​
​
​
​